Literature DB >> 11976988

Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.

Javier García-Samaniego1, Vicente Soriano, José María Miró, Jorge Del Romero, Miguel Bruguera, Jesús Castilla, Juan Ignacio Esteban, Juan Gonźlez, Eduardo Lissen, Alberto Moreno, Santiago Moreno, Ricardo Moreno-Otero, Enrique Ortega, Carmen Quereda, Manuel Rodríguez, José María Sánchez-Tapias.   

Abstract

Co-infection by human immunodeficiency virus and hepatitis B and C viruses is quite common because they share similar routes of transmission. The introduction of highly active antiretroviral therapy has significantly improved the life expectancy of HIV-infected patients in the last few years. However, chronic viral hepatitis represents an emerging cause of morbidity and mortality in this population, either as a result of end-stage liver disease or as a consequence of hepatotoxicity induced by antiretroviral drugs. The main goal of the Consensus Conference was to establish specific recommendations for the management of chronic viral hepatitis B and C in HIV-infected patients. The role of orthotopic liver transplantation for co-infected individuals with end-stage liver disease was also assessed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11976988     DOI: 10.1310/H2CF-3KNA-Q3Y9-C3G1

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  2 in total

1.  T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy.

Authors:  A Arizcorreta; M Márquez; C Fernández-Gutiérrez; E Pérez Guzmán; F Brun; M Rodríguez-Iglesias; J A Girón-González
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

Review 2.  Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Authors:  Miriam Romero; Mayte Pérez-Olmeda; Javier García-Samaniego; Vicente Soriano
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.